• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many suffering from depression, traditional therapies and medication are ineffective. The individual approach to lithium treatment for depression could be the solution.

Cue is an intervention platform that converts sensor data collected from smartphones into personalised micro-interventions for improving mental health. We examined the most effective-fitting personalized ML models to each person using Shapley values, in order to understand their feature predictors. The results revealed distinct characteristics that deterministically changed mood over time.

Predictors of Mood

Depression is a leading cause of mental illness around the world.1 Yet the majority of people suffering from the condition receive treatment. To improve the outcomes, doctors must be able to recognize and treat patients who have the highest chance of responding to certain treatments.

The ability to tailor depression treatments is one method of doing this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will gain the most from certain treatments. They use sensors on mobile phones, a voice assistant with artificial intelligence, and other digital tools. Two grants worth more than $10 million will be used to identify the biological and behavioral predictors of response.

The majority of research on predictors for depression treatment effectiveness has focused on sociodemographic and clinical characteristics. These include demographic factors such as age, sex and educational level, clinical characteristics like the severity of symptoms and comorbidities and biological markers such as neuroimaging and genetic variation.

A few studies have utilized longitudinal data to determine mood among individuals. Many studies do not take into account the fact that moods can vary significantly between individuals. Therefore, it is crucial to create methods that allow the recognition of the individual differences in mood predictors and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can systematically identify distinct patterns of behavior and emotions that differ between individuals.

The team also created a machine learning algorithm to model dynamic predictors for the mood of each person's depression. The algorithm blends the individual differences to create an individual "digital genotype" for each participant.

This digital phenotype has been linked to CAT DI scores, a psychometrically validated symptom severity scale. However the correlation was tinny (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 1003) and varied widely among individuals.

Predictors of symptoms

Depression is the leading cause of disability in the world, but it is often untreated and misdiagnosed. In addition, a lack of effective interventions and stigmatization associated with depression disorders hinder many people from seeking help.

To aid in the development of a personalized treatment plan to improve treatment, identifying the factors that predict the severity of symptoms is crucial. The current methods for predicting symptoms rely heavily on clinical interviews, which aren't reliable and only reveal a few features associated with depression.

Machine learning can increase the accuracy of the diagnosis and treatment of depression by combining continuous digital behavior phenotypes collected from smartphone sensors with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes are able to are able to capture a variety of distinct actions and behaviors that are difficult to document through interviews, and allow for continuous and high-resolution measurements.

The study enrolled University of California Los Angeles (UCLA) students with Moderate Depression Treatment to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29, which was developed under the UCLA Depression Grand Challenge. Participants were directed to online assistance or in-person clinics depending on their depression severity. Patients who scored high on the CAT-DI scale of 35 or 65 students were assigned online support via an instructor and those with a score 75 patients were referred to in-person psychotherapy.

At baseline, participants provided an array of questions regarding their personal demographics and psychosocial characteristics. These included sex, age and education, as well as work and financial status; if they were partnered, divorced or single; their current suicidal thoughts, intentions or attempts; and the frequency with which they drank alcohol. The CAT-DI was used to rate the severity of depression symptoms on a scale ranging from zero to 100. CAT-DI assessments were conducted every other week for participants who received online support and weekly for those receiving in-person support.

Predictors of the Reaction to Treatment

Research is focusing on personalized natural treatment for depression for depression. Many studies are focused on finding predictors that can help doctors determine the most effective drugs ways to treat depression treat each patient. Pharmacogenetics in particular uncovers genetic variations that affect how the human body metabolizes drugs. This allows doctors to select drugs that are likely to be most effective for each patient, while minimizing the time and effort involved in trials and errors, while avoiding side effects that might otherwise slow advancement.

Another approach that is promising is to build models for prediction using multiple data sources, such as the clinical information with neural imaging data. These models can then be used to identify the best combination of variables that is predictive of a particular outcome, such as whether or not a particular medication will improve mood and symptoms. These models can be used to determine the patient's response to a treatment, allowing doctors to maximize the effectiveness of their treatment.

A new generation employs machine learning techniques such as the supervised and classification algorithms, regularized logistic regression and tree-based methods to integrate the effects of multiple variables and improve predictive accuracy. These models have been demonstrated to be useful in predicting the outcome of treatment like the response to antidepressants. These approaches are gaining popularity in psychiatry and it is likely that they will become the norm for the future of clinical practice.

In addition to the ML-based prediction models The study of the underlying mechanisms of depression continues. Recent findings suggest that depression is related to the malfunctions of certain neural networks. This suggests that an individualized depression treatment will be built around targeted therapies that target these circuits to restore normal function.

One way to do this is by using internet-based programs that can provide a more personalized and customized experience for patients. For example, one study discovered that a web-based treatment was more effective than standard care in improving symptoms and providing a better quality of life for people with MDD. Furthermore, a randomized controlled trial of a personalized approach to treating depression showed steady improvement and decreased side effects in a significant percentage of participants.

Predictors of adverse effects

A major challenge in personalized depression treatment is predicting which antidepressant medications will have minimal or no side effects. Many patients have a trial-and error approach, with several medications being prescribed before settling on one that is effective and tolerable. Pharmacogenetics is an exciting new avenue for a more effective and precise method of selecting antidepressant therapies.

There are several predictors that can be used to determine the antidepressant to be prescribed, including gene variations, phenotypes of the patient such as ethnicity or gender, and co-morbidities. However it is difficult to determine the most reliable and valid predictors for a particular homeopathic treatment for depression is likely to require randomized controlled trials with much larger samples than those normally enrolled in clinical trials. This is because the detection of interaction effects or moderators may be much more difficult in trials that focus on a single instance of treatment per participant instead of multiple episodes of treatment over a period of time.

In addition, predicting a patient's response will likely require information on the severity of symptoms, comorbidities and the patient's personal experience of tolerability and effectiveness. At present, only a few easily assessable sociodemographic and clinical variables are believed to be correlated with the response to MDD factors, including gender, age, race/ethnicity and SES, BMI and the presence of alexithymia, and the severity of depressive symptoms.

There are many challenges to overcome when it comes to the use of pharmacogenetics for depression treatment. First, it is essential to have a clear understanding and definition of the genetic factors that cause depression, as well as a clear definition of an accurate predictor of treatment response. Additionally, ethical issues like privacy and the responsible use of personal genetic information must be considered carefully. The use of pharmacogenetics may be able to, over the long term help reduce stigma around mental health treatment and improve treatment outcomes. But, like any other psychiatric treatment, careful consideration and application is necessary. For now, it is recommended to provide patients with a variety of medications for depression that work and encourage them to talk openly with their physicians.